Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Rubella Vaccination

Rubella Vaccination In 1969, in anticipation of the licensing of live rubella virus vaccine, we reviewed the data available from research work with attenuated rubella viruses and considered the prospects for controlling rubella through vaccination.1 Looking ahead in this second year of rubella vaccine use, it is appropriate to pause and to reconsider our earlier comments in the light of the increased experience. Several questions pertaining to vaccine use arise frequently and will be dealt with in some detail. Vaccine Availability During an experimental phase extending from 1965 through 1969, approximately 100,000 persons were inoculated with various attenuated rubella virus preparations. At present, three manufacturers have been licensed in the United States to produce live rubella virus vaccine. These vaccines are HPV-77 DE5 (a derivative of the HPV-77 strain produced in duck embryo cell culture), HPV-77 DK12 (a derivative of the HPV-77 strain produced in dog kidney cell culture), and Cendehill http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Rubella Vaccination

JAMA , Volume 215 (4) – Jan 25, 1971

Loading next page...
 
/lp/american-medical-association/rubella-vaccination-6a8ffMkpGQ

References (25)

Publisher
American Medical Association
Copyright
Copyright © 1971 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.1971.03180170049009
Publisher site
See Article on Publisher Site

Abstract

In 1969, in anticipation of the licensing of live rubella virus vaccine, we reviewed the data available from research work with attenuated rubella viruses and considered the prospects for controlling rubella through vaccination.1 Looking ahead in this second year of rubella vaccine use, it is appropriate to pause and to reconsider our earlier comments in the light of the increased experience. Several questions pertaining to vaccine use arise frequently and will be dealt with in some detail. Vaccine Availability During an experimental phase extending from 1965 through 1969, approximately 100,000 persons were inoculated with various attenuated rubella virus preparations. At present, three manufacturers have been licensed in the United States to produce live rubella virus vaccine. These vaccines are HPV-77 DE5 (a derivative of the HPV-77 strain produced in duck embryo cell culture), HPV-77 DK12 (a derivative of the HPV-77 strain produced in dog kidney cell culture), and Cendehill

Journal

JAMAAmerican Medical Association

Published: Jan 25, 1971

There are no references for this article.